Uttarakhand State Distributes Ivermectin to Combat COVID-19 Following Uttar Pradesh, Goa & Karnataka

Uttarakhand State Distributes Ivermectin to Combat COVID-19 Following Uttar Pradesh, Goa & Karnataka

Since the national Indian guidelines included Ivermectin recently, as reported by TrialSite, the Northern Indian state of Uttarakhand announced it too is now preparing to distribute the antiparasitic drug as a “mass chemoprophylaxis,” following the lead of not only Uttar Pradesh but also Goa and Karnataka. This decision was issued by Chief Secretary Om Prakash to all district magistrates based on the outcomes from a recommendation involving a “state-level clinical technical committee.” With an aim of widespread control of the COVID-19 surge, this measure is in addition to many vaccination drives. The Uttarakhand Health Department and associated district magistrates will deliver an Ivermectin-based home kit, including 12 mg tablets, to families across the state.

The Prophylactic Regimen

Located in the far north of India with about 10.1 million people, the Uttarakhand health department has established a home kit regimen involving 12 mg tablets of Ivermectin to individuals over the age of 15, to be taken twice per day after the breakfast meal and then again after dinner for a period of three days. For children aged 10 to 15 years of age, they will be limited to one daily tablet and those children ages 2 to 10 will receive the drug only upon the advice of a credentialed physician. The regimen is excluded for children under 2 in addition to pregnant women and those suffering from liver diseases. It is reported that the kit comes along with instructions covering both the consumption and age-driven dosage requirements.

Goa & Karnataka Regimens

Both Goa and Karnataka are rolling out mass Ivermectin programs in a bid to reduce infection, transmission, and death rates associated with COVID-19. TrialSite reported two days ago that the State of Goa embraced the national Ivermectin guidelines, and as reported in The Mint and other outlets, Vishwajit Rane, Goa’s Health Minister, declared that all people 18 years and up would have access to the generic drug regardless of COVID-19 status in an aggressive bid to lower infection rates and total deaths associated with SARS-CoV-2.

In Goa, the regimen includes 12 mg taken for five days based on data from purported “expert panels” from Europe. The local press outlets didn’t mention any institutions or names associated with these panels. Interestingly, some medical experts report that this five-day regimen isn’t enough and that as a prophylactic, the therapy should be administered until the contagion is better under control.

Meanwhile, yesterday in Karnataka, C. N. Ashwath Narayan, Deputy Chief Minister and head of the state’s COVID-19 task force, shared with local media that they have procured 10 lakh Ivermectin tablets due to arrive on May 14. The Karnataka government will purchase 25 lakh tablets with the goal of distribution to all hospitals.

World Health Organization Edict

The World Health Organization (WHO) has gone on the record that Ivermectin should only be administered in clinical trials. That message aligns with the European Medicines Agency (EMA) and other groups, such as the U.S. Food and Drug Administration (FDA).

WHO’s Chief Scientist tweeted on Tuesday that “Safety and efficacy are important when using any drug for a new indication. @WHO recommends against the use of ivermectin for #COVID19 except within clinical trials.”

Alternative Position

On the other hand, mounting data from a range of clinical trials have indicated differently as over 50 studies reveal positive outcomes. Those results, however, are critiqued by WHO, EMA, and others that have derived from studies that individually aren’t designed to generate adequate medical evidence. A recent meta-analysis published in the American Journal of Therapeutics led by the Front Line COVID-19 Critical Care Alliance (FLCCC) points to a very different conclusion: that ivermectin in fact should be embraced at least on an emergency use basis depending on what is considered safe and effective outcomes.


  1. Peter Bell the famous footballer? Wow!! Yes, it is hard to get the message out, and there is active suppression going on all over the world. This is the height of suicidal stupidity … or a really sinister global plot.

    I find it interesting that the Indian states’ are using different dosages after all this time. Yes, IVM is very dosage tolerant. I just would have figured that there would be a consensus dosage by this point.

  2. I am sending this message to my friends and relatives and publications/media that I have rabbited on about ivermectin…herein refered to as “other drugs”.
    My apologies for my message about “another drug” other than a vaccine.
    I now realise that publicity for other drugs are forbidden for the greater good of the public.
    “Other drugs” would be in conflict with vaccines thereby eliminating or greatly reducing their (vaccines) effectiveness. I also realise that health officials and govt. officials are stuck with their protocols and are concentrating their efforts on vaccines and PPE’s for the greater good.
    They are bound by their adherance to all vaccine suppliers contracs stipulating that no other drugs are to be promoted in case they “may CONFLICT with their vaccine”.
    Longer term there may be a place for “other drugs” but hopefully many deaths and sickness will be avoided through the quiet use of “other drugs”…ivermectin.
    Please note that this message is clouded in meaningless words like “other drugs” but actually for trialsitenews is actually meaning “ivermectin”.
    If I mention ivermectin in any responses to any other publications it gets deleted… eg: even from “Times of India”.
    I have caused much discomfort for my friends,relatives and acquaintances by advocating this “other drug” (ivermectin) for which I apologise.
    Best wishes 
    Peter Bell

    1. I have noticed that there is a lot of ‘social shaming’ going on of anyone that questions the wisdom of participating in a massive clinical trial of a vaccine technology, with no long term testing.